HISTORICALLY ACCEPTED USE

Tertiary and Quaternary Committee

Executive Summary

Date: June 2019

Medicine (INN): <u>Cisplatin</u> Medicine (ATC): L01XA01

Indication (ICD10 code): Advanced/Metastatic: Various Cancers

Patient population: children and adults
Prevalence of condition: Various cancers
Level of Care: Tertiary and Quaternary

Prescriber Level: Oncologist and haematologist (adult and paediatric)

Current standard of Care: Cisplatin alone or in combination

Efficacy estimates: Established standard of care

Historically accepted use Criteria

	Criteria	Comment
1	The medicine is included in the WHO Model Essential Medicines List, either as a	YES NO
	core or complementary item, for the indication requested.	X
2	The medicine is currently registered by SAHPRA for the indication.	YES NO
		X
3	There is evidence of long-established (prior to 1996*) safe and effective use of	YES NO
	the medicine for the recognised indication in the public health sector.	X
		Comment:
4	There are no new safety or efficacy concerns.	YES NO
		X
		Comment:
5	The budget impact is not expected to be sufficiently large that a de novo review	YES NO
	is justified.	X
		Comment:
6	There is equitable access across the country, and is limited only by the	YES NO
	availability of adequately trained staff and availability of equipment.	Х
		Comment

^{*} The Essential Drugs Programme (EDP) of South Africa was established in terms of the National Drug Policy (NDP) which was implemented in 1996

Recommendation

It is recommended that cisplatin be included as an Essential Medicine for the management of various advanced/metastatic malignancies